Blood transfusions and human recombinant erythropoietin in premature newborn infants

Paula Williamson, Gill Griffiths, Derek Norfolk, Malcolm Levene

Transfusion with concentrated erythrocytes is a common form of treatment in many very premature infants. It is estimated that over 80% of infants requiring intensive care have received at least one blood transfusion as part of their treatment, and 37% more than two. Frequent blood transfusions expose the infants to multiple donors. One survey reported that infants who were given more than one transfusion received blood from a mean of 4.9 donors. There is increasing anxiety concerning the potential adverse effects of blood transfusions and various methods for reducing the need for blood transfusions in sick premature infants have been investigated. In particular, the role of human recombinant erythropoietin has been the subject of a number of controlled studies: we describe an overview of the efficacy of this form of treatment.

Potential hazards of blood transfusion

Transfusion transmitted infection

The acquisition of transfusion related viral infection is a particular anxiety in premature infants, because of their immunological immaturity and the potential for the full clinical expression of diseases such as hepatitis C or HIV infection later in life. Provision of a “safe” blood supply is largely based on donor screening and self-referral. Blood donors in the United Kingdom are routinely screened for syphilis, hepatitis B surface antigen (HBsAg), antibodies to HIV-1 and -2 and, since 1991, antibodies to hepatitis C virus (HCV). The recent controversy over the introduction of routine HCV screening forcibly reminds us that unrecognised infectious agents may be present in the blood supply before effective screening tests are available. Donors with recently acquired viral infection may also occasionally give blood in the “window period” before developing screen detectable antibodies. Blood for premature infants is also screened for antibodies to cytomegalovirus (CMV). CMV antibody screening reduces the risk of transmission to less than 4%, but a small proportion of CMV seronegative donors have mononuclear cells which are positive for CMV DNA by the polymerase chain reaction. Similar arguments may apply to other leucocyte associated viruses, such as HTLV I and II (not routinely screened for in the United Kingdom because of their low prevalence in the donor population).

Residual donor leucocytes

Cellular blood components produced by standard techniques contain clinically important numbers of residual donor leucocytes (2 - 3 x 10⁸ per red cell unit). These “contaminating” leucocytes have been implicated in a range of immunological and infective complications of blood transfusion. Recent data also suggest that leucocytes may generate inflammatory cytokines during storage and cause febrile transfusion reactions. However, HLA-alloimmunisation and non-haemolytic febrile transfusion reactions are a minimal clinical problem in newborn infants, presumably because of their immunological immaturity. Transfusion related graft versus host disease contracted from donor lymphocytes is also rare except in infants with severe congenital defects of cellular immunity. Perhaps of most concern is the potentially “immunosuppressive” effect of transfused leucocytes. Documented changes include reductions in natural killer cell activity and CD4 lymphocytes, an increase in CD8 (suppressor) T cells and B lymphocytes, and impaired secretion of cytokines such as IL-2. These changes have been implicated in the improved survival of patients with renal allografts and in increased rates of cancer recurrence and bacterial infection after surgery. The use of leucocyte depleted or autologous blood products may prevent these complications. Blood transfusion with unscreened donor plasma increases mortality in infants with necrotising enterocolitis who have the Thomson-Friedenreich cryptanti-gen (TCA) exposed on their red cells.

Free radical generation

Free radicals damage biological membranes by inducing lipid peroxidation. This has been suggested as the mechanism for bronchopulmonary dysplasia, retinopathy of prematurity, and intraventricular haemorrhage in premature infants. Ferrous iron fuels the production of free radicals and the premature infant has a very limited capacity to assimilate exogenous iron. Blood transfusion increases iron load of the neonate and this may be an important factor in the development or exacerbation of these complications.

Strategies to reduce the need for transfusion

Iatrogenic blood loss

 Sick premature babies lose a considerable amount of blood as the result of the need for repeated investigations. One recent study...
found that during the first three weeks of life, moderately ill infants weighing ≤1250 g lose almost 50 ml of blood as the result of sampling.\(^1\) This represents more than half the circulating blood volume of these infants and is equivalent to a blood loss of 3.5 l in an adult. Another study has shown that 26% of very low birthweight (VLBW) infants had a cumulative blood loss which exceeded their red blood cell mass at birth.\(^4\) It may be possible to reduce this volume of blood loss by reviewing blood sampling regimens and using smaller volumes of blood in microasys.

**TRANSFUSION NEEDS**

Tissue oxygen delivery depends on respiratory function, tissue perfusion, the haemoglobin concentration and the oxygen dissociation curve of the haemoglobin. There is no scientific basis for currently used transfusion protocols and these vary significantly from neonatal unit to unit. Shannon *et al* have developed conservative transfusion criteria for growing preterm infants in additional oxygen and this has been shown to markedly reduce the number of blood transfusions compared with a traditional less strict policy and with apparently no detrimental effect on the babies.\(^5\)

<table>
<thead>
<tr>
<th>Study (year of publication)</th>
<th>Dose (U/kg/week)</th>
<th>Route of administration</th>
<th>Duration of treatment</th>
<th>Iron</th>
<th>Gestational age for entry (weeks)</th>
<th>Time of randomisation (days of life)</th>
<th>Duration of follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obladen <em>et al</em> (1991)(^2)</td>
<td>500**</td>
<td>Intravenous</td>
<td>6 weeks</td>
<td>3 mg/kg/day</td>
<td>≥200</td>
<td>Day 4</td>
<td>30 days after randomisation</td>
</tr>
<tr>
<td>Shannon <em>et al</em> (1991)(^2)</td>
<td>500**</td>
<td>Intravenous</td>
<td>6 weeks</td>
<td>3 mg/kg/day</td>
<td>≥200</td>
<td>Day 4</td>
<td>30 days after randomisation</td>
</tr>
<tr>
<td>Shannon <em>et al</em> (1992)(^2)</td>
<td>500**</td>
<td>Intravenous</td>
<td>6 weeks</td>
<td>3 mg/kg/day</td>
<td>≥200</td>
<td>Day 4</td>
<td>30 days after randomisation</td>
</tr>
<tr>
<td>Bechensteen <em>et al</em> (1993)(^2)</td>
<td>300</td>
<td>Subcutaneous</td>
<td>Until 7 weeks of age</td>
<td>18 mg/day from day 21 of life (BW&lt;900-1400 g)</td>
<td>28-32</td>
<td>Day 4</td>
<td>30 days after randomisation</td>
</tr>
<tr>
<td>Emmerson <em>et al</em> (1993)(^2)</td>
<td>100-300</td>
<td>Subcutaneous</td>
<td>Until discharge home</td>
<td>6.25 mg from 4 weeks of age</td>
<td>27-33</td>
<td>After day 7</td>
<td>3 months after discharge</td>
</tr>
<tr>
<td>Ohls <em>et al</em> (1993)(^2)</td>
<td>1400</td>
<td>Intravenous</td>
<td>14 days</td>
<td>2 mg/kg/day</td>
<td>N/A</td>
<td>Day 1</td>
<td>15 days after randomisation</td>
</tr>
<tr>
<td>Ohls <em>et al</em> (1993)(^2)</td>
<td>1400</td>
<td>Subcutaneous</td>
<td>10 days</td>
<td>3-5 mg/kg/day</td>
<td>N/A</td>
<td>Day 1</td>
<td>15 days after randomisation</td>
</tr>
<tr>
<td>Soubasi <em>et al</em> (1993)(^2)</td>
<td>300</td>
<td>Subcutaneous</td>
<td>Until 6 weeks of age</td>
<td>3 mg/kg/day from day 15 of life</td>
<td>≥34</td>
<td>Days 3</td>
<td>14-56 days after randomisation</td>
</tr>
<tr>
<td>Maier <em>et al</em> (1994)(^2)</td>
<td>750</td>
<td>Subcutaneous</td>
<td>Until 4250 U/kg received</td>
<td>2 mg/kg/day from day 14</td>
<td>≤34</td>
<td>Days 3</td>
<td>14-56 days after randomisation</td>
</tr>
<tr>
<td>Meyer <em>et al</em> (1994)(^2)</td>
<td>600†</td>
<td>Subcutaneous</td>
<td>6 weeks</td>
<td>2-3 mg/kg/day syringe†</td>
<td>≤34</td>
<td>Days 3</td>
<td>14-56 days after randomisation</td>
</tr>
<tr>
<td>Shannon <em>et al</em> (1995)(^2)</td>
<td>500</td>
<td>Subcutaneous</td>
<td>6 weeks/discharge home</td>
<td>3 mg/kg/day from entry‡</td>
<td>≤34</td>
<td>Days 3</td>
<td>14-56 days after randomisation</td>
</tr>
<tr>
<td>Ishikawa(^7)</td>
<td>400</td>
<td>Subcutaneous</td>
<td>8 weeks</td>
<td>4 mg/kg/day if serum iron below 60 u/g/dl (BW:500-2000 g)</td>
<td>N/A</td>
<td>Days 10-40</td>
<td>11 weeks after randomisation</td>
</tr>
</tbody>
</table>

*When on 70 ml/kg/day enterally, increasing to 6 when >100 ml/kg/day.

** doubled to 1000 after 2-3 weeks if reticulocyte count target not reached.

† Increased on basis of hypochromic cells.

‡ Increase of 150 if % haematocrit reduction.

§ Increasing to 6 when full feeding commenced.

**Overview of r-HuEPO studies**

We included all randomised trials of r-HuEPO injections compared with either placebo,\(^1\) \(^2\) \(^3\) \(^4\) \(^5\) \(^6\) or no injections\(^7\) \(^8\) \(^9\) \(^10\) \(^11\) \(^12\) \(^13\) \(^14\) \(^15\) in premature neonates. This included pilot safety studies and a dose ranging study\(^16\) which were randomised and controlled. Trials fulfilling the above criteria, known to have been discontinued at an interim analysis stage, were also eligible for inclusion. Trials were excluded if r-HuEPO and iron were compared with no injections and no iron, if r-HuEPO was compared with erythrocyte transfusions, and where the trial was non-randomised and/or uncontrolled.

Trials were located through a search of the published findings including abstracts, the Cochrane Collaboration trial register, conference proceedings, and through direct contact with researchers and pharmaceutical companies manufacturing r-HuEPO. The information from 12 completed randomised trials fulfilling the above criteria was ascertained (table 1). Details from one eligible trial\(^17\) were not available at the time of writing. Two unpublished trials were identified,\(^17\) \(^18\) but a further study, mentioned to us by one researcher, has not been verified.

The average gestational age was below 28 weeks in only four studies.\(^1\) \(^2\) \(^3\) \(^4\) \(^5\) \(^6\) \(^7\) \(^8\) \(^9\) \(^10\) \(^11\) \(^12\) \(^13\) \(^14\) \(^15\) \(^16\) \(^17\) Eligibility criteria based on respiratory support varied widely. Studies evaluated both prophylactic (treatment started before the third week of life) and therapeutic (started after the third week of life) use of r-HuEPO. There was a very wide variation in the weekly r-HuEPO dose (70-1400 U/kg) and the length of treatment varied from 10 days to eight weeks on discharge home from hospital. There was variation in iron and vitamin E supplementation but, by design this overview included only trials with no planned
differential supplementation. Such clinical heterogeneity indicated by the wide range of transfusion episodes in the control groups (table 2) makes a single effect estimate from a quantitative meta-analysis difficult to interpret.

Trial quality varied considerably. Of the 12 completed trials, eight were reported to be blind and there were no reports of this having been broken.13 16 21-24 The method of randomisation was poorly described in most studies. The imbalance in numbers assigned to each group in one trial with planned randomisation26 was due to chance (Soubasi V, personal communication). Randomised infants were excluded from the analysis in three studies.16 21 25 Strict transfusion criteria were not applied in several.10 22 26

Publication bias may affect the overview, and setting a minimum number of infants/events for trial inclusion may reduce this bias. As the main aim was to collate information on safety, results from all eligible trials are presented (table 2). However, publication bias may affect the overview of efficacy, although less weight is given to smaller trials in the meta-analysis.

There was no obvious trend towards increased total mortality in infants treated with r-HuEPO from these studies. Longer term follow up, however, went beyond the sixth month of life in only three studies. No increase in the incidence of neutropenia has been reported. There are conflicting results with respect to septicaemia in three studies.13 17 24

The studies consistently report that r-HuEPO treatment is associated with some reduction in the proportion of infants transfused (fig 1). Taken as a whole, there is strong evidence to suggest that rHuEPO reduces the need for blood transfusion (Cochran-Mantel-Haentzel $\chi^2$ statistic = 35.2, 1 df; $P<0.0001$). This conclusion is unchanged after the exclusion of trials terminated early26 or not analysed by intention to treat.18 23 25 The evidence against homogeneity of treatment effects in the trials is minimal ($\chi^2$ statistic = 17.3, 11 df; $P=0.099$). Indeed, after exclusion of the trials terminated early or not analysed by intention to treat, which may show exaggerated effect sizes, there is no evidence of a lack of homogeneity ($\chi^2$ statistic = 6.8, 7 df; $P > 0.1$). One of the excluded studies25 was a pilot using only a low weekly dose of r-HuEPO. The conclusions from this overview must be viewed in terms of the fact that all the studies recruited small numbers of infants; only two studies enrolled more than 100 subjects.

**Conclusions**

Clearly, there is no single strategy which can reduce the exposure of premature infants to blood transfusions. It has been estimated that 90% of all erythrocyte transfusions in neonates are for replacement of iatrogenic losses.28

---

**Table 2** Summary of data for transfusion and mortality endpoints in randomised controlled trials of r-HuEPO in premature infants

<table>
<thead>
<tr>
<th>Study (year of publication)</th>
<th>Transfusion</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r-HuEPO (No/%)</td>
<td>Control (No/%)</td>
</tr>
<tr>
<td>Obladen et al (1991)15</td>
<td>23/38 (61)</td>
<td>29/45 (64)</td>
</tr>
<tr>
<td>Shannon et al (1991)20</td>
<td>6/10 (60)</td>
<td>8/10 (80)</td>
</tr>
<tr>
<td>Shannon et al (1992)20</td>
<td>1/40 (25)</td>
<td>3/40 (75)</td>
</tr>
<tr>
<td>Bechensteen et al (1993)22</td>
<td>0/14 (0)</td>
<td>4/15 (27)</td>
</tr>
<tr>
<td>Emmerson et al (1993)16</td>
<td>7/15 (47)</td>
<td>7/80 (88)</td>
</tr>
<tr>
<td>Ohls et al (1993)18</td>
<td>2/10 (20)</td>
<td>7/10 (70)</td>
</tr>
<tr>
<td>Ohls et al (1994)19</td>
<td>1/10 (10)</td>
<td>4/50 (80)</td>
</tr>
<tr>
<td>Soubasi et al (1993)26</td>
<td>19/25 (76)</td>
<td>18/19 (95)</td>
</tr>
<tr>
<td>Maier et al (1994)20</td>
<td>60/120 (50)</td>
<td>81/121 (67)</td>
</tr>
<tr>
<td>Meyer et al (1994)17</td>
<td>6/40 (15)</td>
<td>17/40 (43)</td>
</tr>
<tr>
<td>Shannon et al (1995)13</td>
<td>44/77 (57)</td>
<td>55/80 (69)</td>
</tr>
<tr>
<td>Ishikawa15</td>
<td>2/32 (6)</td>
<td>12/30 (40)</td>
</tr>
</tbody>
</table>

* includes one death at 1 year.
† where data on 125 infants with six month follow up in clinics included.

---

**Figure 1** Odds ratio of the need for at least one transfusion (95% confidence interval) in 12 trials of r-HuEPO. Odds ratio less than unity represent beneficial effects. Trial size is the total number of patients with transfusion data given; meta-analysis assumes a fixed effects model.
Strategies directed at critically reviewing the need for all the blood samples taken in the neonatal nursery, and further developments of micromethods, may reduce this degree of unacceptable blood loss.

A simple policy of satellite packs of blood, allowing up to eight transfusions from a single donor and extending the expiry date of unused blood to 35 days, has significantly reduced the exposure of babies to multiple donors.\(^2\)\(^,\)\(^3\)

Our overview has shown that r-HuEPO seems to have a potential role in reducing the need for blood transfusions as the result of anaemia of prematurity. All studies reported some degree of reduction in the proportion of infants transfused after r-HuEPO treatment.

The results of this overview do not suggest any adverse effect of r-HuEPO on either early mortality or neutropenia. These trials, however, involve small numbers of infants and rarely followed them beyond six months of life. A number of important questions remain unresolved with respect to r-HuEPO. It is the most immature infants who are most likely to develop anaemia of prematurity and the dose response relation of r-HuEPO in these most immature babies is not known. The requirements for iron, folate, and other supplements required by babies receiving r-HuEPO have not been well studied. Further large multicentre trials with longer term follow up, which address health economic issues, need to be undertaken before recommendations about the routine use of r-HuEPO can be made.

An approach to avoiding blood transfusion using r-HuEPO alone is of limited benefit, because of the massive iatrogenic blood losses incurred in the first few weeks of life before r-HuEPO is likely to have a significant effect. Shannon\(^1\) recommends the routine administration of r-HuEPO in preterm infants, but this study also reported that the infants in their study had received an average of 3.5 transfusions before enrolment. Shannon showed that the r-HuEPO group required a mean (SD) of 1.1 (1.5) transfusions compared with 1.6 (1.7) in the control group.\(^1\) This modest reduction in the number of red cell transfusions may, however, not be clinically useful. Volume of blood given may be more important and in their study a mean (SD) of 16.5 (23) ml of packed red cells was transfused in the r-HuEPO group compared with 23.9 (25.7) ml in the control group.

Further research is required to evaluate the effects of restrictive transfusion regimens in premature infants. This may be the most cost effective way of reducing exposure to multiple blood transfusions.

---

Blood transfusions and human recombinant erythropoietin in premature newborn infants.

P Williamson, G Griffiths, D Norfolk and M Levene

Arch Dis Child Fetal Neonatal Ed 1996 75: F65-F68
doi: 10.1136/fn.75.1.F65